IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Opus Genetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.82−0.02 (-0.52%)
Close on Oct 19, 2026
- Market cap
- $425.49M
- P/E (TTM)
- –
- Dividend yield
- –
Opus Genetics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Market Cap | $317.81M | $166.30M |
| Enterprise Value | $229.00M | $88.19M |
| PS Ratio | 32.25 | 3.65 |
Enterprise value
| Measure | Opus Genetics | Industry median |
|---|---|---|
| EV / Sales | 23.23 | 2.51 |
Income (trailing twelve months)
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Revenue | $9.86M | $58.34M |
| Operating Income | -$50.61M | -$21.40M |
| Pretax Income | -$107.61M | -$14.34M |
| Net Income | -$107.61M | -$22.46M |
| EBITDA | -$50.61M | -$16.91M |
| EPS (Diluted) | -$1.35 | -$0.83 |
Margins
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Operating Margin | -513.5% | -44.0% |
| Pretax Margin | -1091.8% | -13.3% |
| Profit Margin | -1091.8% | -40.2% |
| EBITDA Margin | -513.5% | -30.2% |
Returns
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -4796.5% | -53.2% |
| Return on Assets (ROA) | -163.5% | -40.9% |
| Return on Capital Employed (ROCE) | -59.3% | -38.1% |
Growth
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -36.1% | 5.96% |
| Revenue Growth (3Y CAGR) | -29.1% | 2.25% |
Balance sheet
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $88.81M | $61.43M |
| Net Cash (Debt) | $88.81M | $15.35M |
| Net Cash Per Share | $1.07 | $0.66 |
| Equity (Book Value) | -$12.99M | $49.09M |
| Book Value Per Share | -$0.16 | $1.37 |
| Tangible Book Value | -$12.99M | $23.52M |
| Working Capital | $85.09M | $76.81M |
Financial position
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Current Ratio | 12.19 | 3.34 |
| Quick Ratio | 11.81 | 2.44 |
| Interest Coverage | -186.06 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Operating Cash Flow | -$40.67M | -$12.35M |
Efficiency
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Asset Turnover | 0.15 | 0.39 |
| Revenue Per Employee | $365.04K | $404.87K |
| Profits Per Employee | -$3.99M | -$703.34K |
| Employee Count | 27 | 74 |
Dividends and yields
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Earnings Yield | -33.9% | -23.3% |
| Buyback Yield | -2.41% | -0.59% |
| Shareholder Yield | -2.41% | 0.00% |
Shares
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Shares Outstanding | 83,195,800 | 58,127,000 |
| Shares Change (YoY) | 127.3% | 10.9% |
| Shares Change (QoQ) | 15.7% | 0.54% |
| Float | 51,245,700 | 49,136,700 |
| Shares Held by Insiders | 38.4% | 11.6% |
| Shares Held by Institutions | 72.8% | 59.4% |
Taxes
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Opus Genetics | Industry median |
|---|---|---|
| Altman Z-Score | -2.74 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Opus Genetics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.